▶ 調査レポート

尿路感染(UTI)治療薬の世界市場:薬剤タイプ別(ペニシリン・複合治療薬、キノロン類、セファロスポリン、アミノグリコシド抗体、スルホンアミド、アゾール・アンフォテリシンB、テトラサイクリン、ニトロフラン、その他)、適応症別(複雑性UTI、再発性複雑性UTI、非複雑性UTI、神経因性膀胱炎)、地域別分析

• 英文タイトル:Global Urinary Tract Infection Therapeutics Market - Segmented by Type of Drug, and Indication - Growth, Trends and Forecasts (2018 - 2023)

Mordor Intelligenceが調査・発行した産業分析レポートです。尿路感染(UTI)治療薬の世界市場:薬剤タイプ別(ペニシリン・複合治療薬、キノロン類、セファロスポリン、アミノグリコシド抗体、スルホンアミド、アゾール・アンフォテリシンB、テトラサイクリン、ニトロフラン、その他)、適応症別(複雑性UTI、再発性複雑性UTI、非複雑性UTI、神経因性膀胱炎)、地域別分析 / Global Urinary Tract Infection Therapeutics Market - Segmented by Type of Drug, and Indication - Growth, Trends and Forecasts (2018 - 2023) / B-MOR-040932資料のイメージです。• レポートコード:B-MOR-040932
• 出版社/出版日:Mordor Intelligence / 2018年2月
• レポート形態:英文、PDF、117ページ
• 納品方法:Eメール(受注後2営業日)
• 産業分類:医療・バイオ
• 販売価格(消費税別)
  Single User(1名様用)¥450,500 (USD4,250)▷ お問い合わせ
  Team User(7名様用)¥477,000 (USD4,500)▷ お問い合わせ
  Corporate User¥927,500 (USD8,750)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本資料は、尿路感染(UTI)治療薬の世界市場について調べ、尿路感染(UTI)治療薬の世界規模、市場動向、市場環境、薬剤タイプ別(ペニシリン・複合治療薬、キノロン類、セファロスポリン、アミノグリコシド抗体、スルホンアミド、アゾール・アンフォテリシンB、テトラサイクリン、ニトロフラン、その他)分析、適応症別(複雑性UTI、再発性複雑性UTI、非複雑性UTI、神経因性膀胱炎)分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。
・イントロダクション
・エグゼクティブサマリー
・尿路感染(UTI)治療薬の世界市場インサイト
・尿路感染(UTI)治療薬の世界市場環境
・尿路感染(UTI)治療薬の世界市場動向
・尿路感染(UTI)治療薬の世界市場規模
・尿路感染(UTI)治療薬の世界市場規模:薬剤タイプ別(ペニシリン・複合治療薬、キノロン類、セファロスポリン、アミノグリコシド抗体、スルホンアミド、アゾール・アンフォテリシンB、テトラサイクリン、ニトロフラン、その他)
・尿路感染(UTI)治療薬の世界市場規模:適応症別(複雑性UTI、再発性複雑性UTI、非複雑性UTI、神経因性膀胱炎)
・尿路感染(UTI)治療薬の世界市場:地域別市場規模・分析
・尿路感染(UTI)治療薬の北米市場規模・予測
・尿路感染(UTI)治療薬のアメリカ市場規模・予測
・尿路感染(UTI)治療薬のヨーロッパ市場規模・予測
・尿路感染(UTI)治療薬のアジア市場規模・予測
・尿路感染(UTI)治療薬の日本市場規模・予測
・尿路感染(UTI)治療薬の中国市場規模・予測
・尿路感染(UTI)治療薬のインド市場規模・予測
・尿路感染(UTI)治療薬の韓国市場規模・予測
・関連企業情報・競争状況

The global urinary tract infection therapeutics market is expected to register a CAGR of 3.5% during the forecast period 2018 to 2023. North America dominates the market due to high Urinary Tract Infection (UTI) detection along with increasing diabetes prevalence in the region.

Increasing Prevalence of Diabetes and Kidney Stones

According to World Health Organization (WHO), in 1980 there were 108 million people suffering from diabetes, this number increased to 422 million in 2014. While the prevalence of diabetes in adults increased from 4.7% in 1980 to 8.5% in 2014. This trend of increment in diabetes prevalence rate among adults is expected to continue in the forecast period. Therefore with increasing prevalence, the number of UTI increases, and with increase in UTI, the demand for drugs increases. Thus increasing prevalence of diabetes worldwide is expected to act as a major driver for the global urinary tract infection therapeutics market.
In addition, launch of combination drugs which are more effective and increasing geriatric population are also expected to boost the growth of urinary tract infection therapeutics market.

Adverse Effects Associated with the Use of Medication

According to Centers for Education & Research on Therapeutics, over 2 million cases of Adverse Drug Reactions (ADRs) are reported every year, out of which there are approximately 100,000 deaths. According to FDA, it is also estimated that each year over 350,000 ADRs occur in U.S nursing homes alone. With such increasing cases of ADRs being reported in every corner of the globe, there is averseness among population for the adoption of drugs, which is acting as a major restraint for the urinary tract infection therapeutics market.
Additionally, lack of awareness about the prevalence of UTI in developing and underdeveloped nations is restraining the growth of the market.

North America to Dominate the Market

The Urinary Tract Infection Therapeutics market is segmented by Drug type, Indication type and geography. By geography it is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa and South America.
North America dominates the urinary tract infection therapeutics market due to high UTI detection along with increasing diabetes prevalence in the region. Europe is also expected to boost the UTI therapeutics market owing to increased accessibility to healthcare facilities along with high UTI prevalence among the population.

Key Developments in the Market

• August 2017: FDA approved Vabomere for adults. Vabomere is an antibacterial drug which is used for the treatment of complicated urinary tract infections (cUTI) and pyelonephritis (a type of kidney infection caused by specific bacteria). Vabomere contains meropenem and vaborbactam.
• December 2017: F.D.A has accepted for review of NDA (New Drug Application) submitted by Achaogen for plazomicin to treat cUTI including pyelonephritis and bloodstream infections (BSI), and has set a target action date under Prescription Drug User Fee Act (PDUFA) on june, 2018.

Key players: PFIZER LIMITED, BOEHRINGER INGELHEIM, BAYER AG, GLAXOSMITHKLINE PLC, NOVARTIS AG, F. HOFFMANN-LA ROCHE LTD, JOHNSON & JOHNSON, ASTRAZENECA, CIPLA INC and MERLION PHARMA.

Reasons to Purchase this Report

• Market analysis for the Global Urinary Tract Infection Therapeutics Market, with region-specific assessments and competition analysis on a global and regional scale.
• Analyzing various perspectives of the industry with the help of Porter’s five forces analysis
• The treatment type that is expected to dominate the market
• Regions that are expected to witness fastest growth during the forecast period
• Identify the latest developments, market shares and strategies employed by the major market players.
• 3 months analyst support along with the Market Estimate sheet in excel.

Customization of the Report

• This report can be customized to meet your requirements. Please connect with our analyst, who will ensure you get a report that suits your needs.

レポート目次

1. INTRODUCTION
1.1 MARKET DEFINITION
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. KEY INFERENCES
5. MARKET OVERVIEW
5.1 CURRENT MARKET SCENARIO
5.2 PORTER’S FIVE FORCES ANALYSIS
5.2.1 BARGAINING POWER OF SUPPLIERS
5.2.2 BARGAINING POWER OF CONSUMERS
5.2.3 THREATS OF NEW ENTRANTS
5.2.4 THREAT OF SUBSTITUTE PRODUCT AND SERVICES
5.2.5 COMPETITIVE RIVALRY WITHIN THE INDUSTRY
6. DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES ANALYSIS (DROC)
6.1 MARKET DRIVERS
6.1.1 INCREASING PREVALENCE OF DIABETES AND KIDNEY STONES
6.1.2 LAUNCH OF COMBINATION DRUGS
6.1.3 INCREASING GERIATRIC POPULATION
6.2 MARKET RESTRAINTS
6.2.1 ADVERSE EFFECTS ASSOCIATED WITH THE USE OF MEDICATION
6.2.2 LACK OF AWARENESS IN DEVELOPING AND UNDERDEVELOPED NATIONS
6.3 OPPORTUNITIES
6.4 KEY CHALLENGES
7. MARKET SEGMENTATION
7.1 SEGMENTATION-BY DRUG TYPE
7.1.1 PENICILLIN & COMBINATIONS
7.1.2 QUINOLONES
7.1.3 CEPHALOSPORIN
7.1.4 AMINOGLYCOSIDE ANTIBODIES
7.1.5 SULPHONAMIDES
7.1.6 AZOLES & AMPHOTERICIN B
7.1.7 TETRACYCLINE
7.1.8 NITROFURANS
7.1.9 OTHERS
7.2 SEGMENTATION-BY INDICATION TYPE
7.2.1 COMPLICATED UTI
7.2.2 RECURRING COMPLICATED UTI
7.2.3 UNCOMPLICATED UTI
7.2.4 NEUROGENIC BLADDER INFECTION
7.3 SEGMENTATION-BY GEOGRAPHY
7.3.1 NORTH AMERICA
7.3.1.1 UNITED STATES
7.3.1.2 CANADA
7.3.1.3 MEXICO
7.3.2 EUROPE
7.3.2.1 FRANCE
7.3.2.2 GERMANY
7.3.2.3 UNITED KINGDOM
7.3.2.4 ITALY
7.3.2.5 SPAIN
7.3.2.6 REST OF EUROPE
7.3.3 ASIA-PACIFIC
7.3.3.1 CHINA
7.3.3.2 JAPAN
7.3.3.3 INDIA
7.3.3.4 AUSTRALIA & NEW ZEALAND
7.3.3.5 SOUTH KOREA
7.3.3.6 REST OF ASIA-PACIFIC
7.3.4 MIDDLE EAST & AFRICA
7.3.4.1 GCC
7.3.4.2 SOUTH AFRICA
7.3.4.3 REST OF THE MIDDLE EAST & AFRICA
7.3.5 SOUTH AMERICA
7.3.5.1 BRAZIL
7.3.5.2 ARGENTINA
7.3.5.3 REST OF SOUTH AMERICA
8. COMPETITIVE LANDSCAPE
8.1 MERGERS & ACQUISITION ANALYSIS
8.2 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS
8.3 NEW PRODUCTS LAUNCHES
9. KEY PLAYERS
9.1 PFIZER LIMITED
9.2 BOEHRINGER INGELHEIM
9.3 BAYER AG
9.4 GLAXOSMITHKLINE PLC
9.5 NOVARTIS AG
9.6 F. HOFFMANN-LA ROCHE LTD
9.7 JOHNSON & JOHNSON
9.8 ASTRAZENECA
9.9 CIPLA INC
9.10 MERLION PHARMA
9.11 OTHERS
10. FUTURE OF THE MARKET